Acumen Pharmaceuticals, Inc. (ABOS)
Market Cap | 136.38M |
Revenue (ttm) | n/a |
Net Income (ttm) | -55.94M |
Shares Out | 60.08M |
EPS (ttm) | -1.06 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 274,942 |
Open | 2.380 |
Previous Close | 2.385 |
Day's Range | 2.230 - 2.400 |
52-Week Range | 1.810 - 11.310 |
Beta | 0.15 |
Analysts | Strong Buy |
Price Target | 12.60 (+455.07%) |
Earnings Date | Aug 6, 2024 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price forecast is $12.6, which is an increase of 455.07% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/y/n/press11-2428951.jpg)
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
CHARLOTTESVILLE, Va., May 14, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeuti...
![](https://cdn.snapi.dev/images/v1/6/u/conf11-2427990.jpg)
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
![](https://cdn.snapi.dev/images/v1/2/q/press18-2419593.jpg)
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
![](https://cdn.snapi.dev/images/v1/x/d/press3-2417803.jpg)
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
![](https://cdn.snapi.dev/images/v1/z/z/conf1-2416033.jpg)
Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
CHARLOTTESVILLE, Va., May 07, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeuti...
![](https://cdn.snapi.dev/images/v1/n/j/press2-2373249.jpg)
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic solub...
![](https://cdn.snapi.dev/images/v1/s/d/press12-2356196.jpg)
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease
CHARLOTTESVILLE, Va. and BASEL, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic sol...
![](https://cdn.snapi.dev/images/v1/7/9/press18-2341354.jpg)
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
CHARLOTTESVILLE, Va., March 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeu...
![](https://cdn.snapi.dev/images/v1/2/h/conf8-2331771.jpg)
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeu...
![](https://cdn.snapi.dev/images/v1/o/o/press13-2320876.jpg)
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic solub...
![](https://cdn.snapi.dev/images/v1/m/v/press18-2315336.jpg)
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting
- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the brain in early AD
![](https://cdn.snapi.dev/images/v1/2/k/conf15-2285696.jpg)
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting
- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD
![](https://cdn.snapi.dev/images/v1/f/q/press16-2254970.jpg)
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic solubl...
![](https://cdn.snapi.dev/images/v1/0/t/conf4-2217309.jpg)
Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic solubl...
![](https://cdn.snapi.dev/images/v1/q/h/press1-2154156.jpg)
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeut...
![](https://cdn.snapi.dev/images/v1/n/h/press18-2154153.jpg)
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeut...
![](https://cdn.snapi.dev/images/v1/s/s/press18-2145095.jpg)
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic tha...
![](https://cdn.snapi.dev/images/v1/g/0/conf15-2142457.jpg)
Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company develo...
![](https://cdn.snapi.dev/images/v1/s/u/press12-2141213.jpg)
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology
Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193 Expect to initiate Phase 1 development in mid-2024 to compare pharmaco...
![](https://cdn.snapi.dev/images/v1/q/9/press2-2137451.jpg)
Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference
CHARLOTTESVILLE, Va., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic solubl...
![](https://cdn.snapi.dev/images/v1/l/r/conf11-2089219.jpg)
Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's During Symposium at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD)
CHARLOTTESVILLE, Va. and INDIANAPOLIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that tar...
![](https://cdn.snapi.dev/images/v1/l/4/conf16-2070008.jpg)
Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that ta...
![](https://cdn.snapi.dev/images/v1/w/o/conf13-2052365.jpg)
Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference
CHARLOTTESVILLE, Va. and CARMEL, Ind., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that ta...
![](https://cdn.snapi.dev/images/v1/2/a/press4-2011422.jpg)
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing ...
![](https://cdn.snapi.dev/images/v1/y/i/conf20-1999820.jpg)
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing ...